Consort Medical (LON:CSRT) was upgraded by stock analysts at Numis Securities to an “add” rating in a research report issued on Thursday. The firm currently has a GBX 1,333 ($18.69) price target on the stock. Numis Securities’ price target points to a potential upside of 10.90% from the stock’s current price.
A number of other brokerages also recently issued reports on CSRT. Shore Capital restated a “buy” rating on shares of Consort Medical in a research report on Tuesday, December 5th. N+1 Singer lowered shares of Consort Medical to a “hold” rating in a research report on Tuesday, December 5th. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 1,250 ($17.53) price target on shares of Consort Medical in a research report on Thursday, November 9th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 1,203.60 ($16.88).
Shares of Consort Medical (LON:CSRT) traded down GBX 6 ($0.08) on Thursday, hitting GBX 1,202 ($16.85). 98,155 shares of the stock were exchanged, compared to its average volume of 14,139. Consort Medical has a 52 week low of GBX 976.09 ($13.69) and a 52 week high of GBX 1,224 ($17.16). The company has a market cap of $592.38 and a P/E ratio of 3,005.00.
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.